^
BIOMARKER:

EGFR exon 21 mutation

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR exon 21 mutation
NSCLC
erlotinib + ramucirumab
Sensitive: B - Late Trials
EGFR exon 21 mutation
NSCLC
icotinib
Sensitive: B - Late Trials
EGFR exon 21 mutation
NSCLC
gefitinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 21 mutation
NSCLC
erlotinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 21 mutation
NSCLC
erlotinib + anlotinib
Sensitive: C3 – Early Trials
EGFR exon 21 mutation
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
EGFR exon 21 mutation
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
EGFR exon 21 mutation
LUAD
erlotinib
Sensitive: C3 – Early Trials
EGFR exon 21 mutation
NSCLC
dacomitinib
Sensitive: C3 – Early Trials
EGFR exon 21 mutation
NSCLC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR exon 21 mutation
Small Cell Lung Cancer
gefitinib
Sensitive: C4 – Case Studies